This dual suppression aligns with the therapeutic strategy of targeting both PI3K/AKT/mTOR and MAPK/ERK pathways, which are often co-activated in thyroid cancers — especially in aggressive subtypes — and contribute to tumor survival, proliferation, and therapeutic resistance (19-21). The gene discussed is AKT1; the disease is thyroid cancer.